CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Cash Flows from Operating Activities:
Net loss	$ (8,479)	$ (2,819)
Non-cash items:
Depreciation and amortization	27,437	26,415
Impairment of assets	48,721	21,170
Share-based compensation expense	4,730	3,379
Deferred tax benefit	(5,309)	0
Provision for losses on accounts receivable and inventory	(1,378)	(352)
Other non-cash operating activities	50	19
Change in operating assets and liabilities:
Change in accounts receivable	22,518	(1,577)
Change in inventories	(37,414)	(15,058)
Change in prepaid income taxes	(3,228)	72
Change in other assets and other liabilities	(8,208)	(1,214)
Change in accounts payable and accrued expenses	(36,812)	(6,913)
Net cash provided by operating activities	2,628	23,122
Cash Flows from Investing Activities:
Capital expenditures	(8,249)	(27,514)
Proceeds from divestiture	9,808	0
Proceeds from sale of property, plant and equipment	302	250
Net cash provided by (used in) investing activities	1,861	(27,264)
Cash Flows from Financing Activities:
Net increase in short-term loans	90,000	0
Term loan borrowings	0	347,780
Repayment of term loan borrowings	(4,375)	(253,728)
Proceeds from employee stock purchase plan	1,830	1,780
Proceeds from exercise of stock options	3,635	2,831
Share repurchases	(75,000)	(80,000)
Net cash provided by financing activities	16,090	18,663
Effect of exchange rates on cash and cash equivalents	304	(2,584)
Net Change in Cash and Cash Equivalents	20,883	11,937
Cash and Cash Equivalents at Beginning of Period	169,351	180,169
Cash and Cash Equivalents at End of Period	190,234	192,106
Supplemental Disclosures of Cash Flow Information:
Interest paid	3,535	2,361
Income taxes paid	3,078	1,817
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 2,973	$ 1,799